While all eyes are on the Indian industry – known for its ability to produce generic drugs at a fraction of the cost – to ...

How will India’s leading drugmaker handle legal setbacks, volatile market trends, and competition in generics and specialty products?

The Cigna Group posted strong Q3 2024 results, yet CI stock is down nearly 20% from its 52-week high. See why this may ...

Although it's about four times the price of table sugar, allulose is considered 70% as sweet and nearly calorie-free. However, health experts caution that further research is needed on its long-term ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Canaccord Genuity analyst Aravinda Galappatthige downgraded the rating on BCE (BCE – Research Report) to a Hold yesterday, setting a ...

BCE's shares were under pressure Monday after the Canadian telecom company struck a roughly 5 billion Canadian dollars ($3.6 billion) deal to buy regional broadband provider Ziply Fiber but will pause ...

Indian generic injectables maker Gland Pharma reported a drop in second-quarter profit on Monday, hurt by lower sales in its Europe business and temporary production issues at its French ...

The share price of Cipla has formed a higher base above the 200-day EMA, indicating a potential resumption of the uptrend. It ...

Join us on the Cipla Stock Liveblog, your hub for real-time updates and comprehensive analysis on a prominent stock. Stay in ...

Cipla share price had fallen after the company's September quarter results as analysts cut their target price, citing weaker than expected domestic business and challenges in its key products.

Leading drug maker Cipla shares today saw a steep rally of 10% after the USFDA classified its Goa facility as a Voluntary Action Indicated (VAI) status, according to its BSE filing. Cipla shares ...